Global Idiopathic Intracranial Hypertension Treatment Market Report and Forecast 2024-2032

Global Idiopathic Intracranial Hypertension Treatment Market Outlook

The global idiopathic intracranial hypertension treatment market size is estimated to grow with a CAGR of 4.27% during the forecast period of 2024-2032. The market growth can be attributed to the increase in the number of obese people and rising ageing population, who are more prone to the condition.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Idiopathic Intracranial Hypertension Insights

Increased pressure inside the skull characterizes Intracranial Hypertension (IH). Intracranial refers to inside the skull, and hypertension refers to high blood pressure. Intracranial hypertension is indicated by an abnormally high pressure in the fluid that surrounds the brain (cerebrospinal fluid or CSF). Elevated CSF pressure can result in two complications: severe headache and visual loss. 

If the elevated CSF pressure is not treated, it can lead to permanent vision loss or blindness. Former names for IH include pseudotumour cerebri and benign intracranial hypertension, both of which are now considered incorrect. These names do not adequately describe the disorder and minimise its severity.

Women are more likely than men to develop IIH. Women account for approximately 19% of people with idiopathic intracranial hypertension. The majority are between the age group of 20 and 50.

A sudden, severe headache is the most common symptom of intracranial hypertension. Sometimes the headache is so severe that it wakes the patient up. People suffering from IIH may experience changes in their vision. One may experience double vision or unexpected blind spots. Symptoms of intracranial hypertension may also include:

• Fatigue

• Headaches

• Peripheral (side) vision loss

• Vomiting and nausea

• Shoulder and neck discomfort

• Blindness is only temporary

• Tinnitus (ringing ears)

IIH has an unknown cause. If a cause is found, the condition is referred to as secondary intracranial hypertension rather than idiopathic intracranial hypertension. Cerebrospinal fluid surrounds the brain and spinal cord, protecting these vital tissues from injury. This fluid is produced in the brain and is eventually absorbed into the bloodstream at a rate that allows the brain pressure to remain constant. The increased intracranial pressure caused by pseudotumour cerebri could be due to a problem with the absorption process. 

According to the idiopathic intracranial hypertension treatment market research report, the market can be categorised into the following segments: 

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Market Breakup by Diagnostic Method

• Carbonic Anhydrase Inhibitors
  • Acetazolamide
  • Methazolamide
  • Others
• Loop Diuretics
  • Furosemide
  • Others
• Corticosteroids

• Anticonvulsant
  • Topiramate
• Others

Market Breakup by Treatment Channels

• Public

• Private

Market Breakup by Region

• North America
  • United States of America
  • Canada
• Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Others
• Asia Pacific
  • China
  • Japan 
  • India
  • ASEAN
  • Australia
  • Others
• Latin America
  • Brazil
  • Argentina
  • Mexico
  • Others
• Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Idiopathic Intracranial Hypertension Epidemiology

Idiopathic intracranial hypertension affects about one in every 100,000 people. Obesity affects approximately 20 young females out of every 100,000.

Therapeutic Landscape of Idiopathic Intracranial Hypertension Treatment Market

In patients with idiopathic intracranial hypertension (IIH), the treatment goal is to preserve optic nerve function while managing increased intracranial pressure (ICP). Obese patients are repeatedly advised to lose weight and eat a low-sodium diet. Exogenous agents that may be linked to increased ICP, should be avoided. The administration of acetazolamide in a dose-proportional to the patient's symptoms, tolerance, and visual function is the first-line treatment.

When there is evidence of progressive visual field loss despite maximal medical treatment, urgent surgical intervention should be considered.

One of the commonly held beliefs about this condition is that pregnancy worsens or causes the onset of symptomatic IIH. However, there is currently little statistical evidence of a causal relationship between pregnancy and IIH, aside from the fact that pregnancy is common in the age group and gender most affected by IIH.

Global Idiopathic Intracranial Hypertension Treatment Market Drivers and Restraints

Factors like the rapid increase in the number of obese people and an ageing population who are more prone to the condition, along with the tremendous growth in obesity due to sedentary lifestyles, are driving the market growth. The rising demand for targeted medicines to treat the condition's complications and the high prevalence of idiopathic intracranial hypertension among women worldwide have a significant impact on the market. The demand is likely to grow further across the globe, especially in North America due to the region's advanced healthcare technology.

On the other hand, the high treatment costs and poor reimbursement policies, particularly in the price-sensitive sector, are expected to hinder the market growth. 

Idiopathic Intracranial Hypertension Treatment Market Competitive Landscape

The report gives an in-depth analysis of the key players involved in the global idiopathic intracranial hypertension treatment market, sponsors manufacturing the therapies, and putting them through trials to get FDA approvals. The companies included in the market are as follows:  

• Teva Pharmaceutical Industries Ltd

• Mylan N.V.

• Pfizer, Inc.

• Upsher-Smith Laboratories, LLC

• Merck & Co., Inc.

• Janssen Pharmaceuticals, Inc. (Johnson & Johnson)

• Astellas Pharma Inc.

• AbbVie Inc.

• Cadila Healthcare Ltd.

• Sanofi

• Sun Pharmaceutical Industries Ltd.

Key Highlights of the Report